EyePoint provides 2026 clinical milestones; ~$300M cash; wet AMD data mid-2026

EyePoint, Inc.

Phase 3 LUGANO (432 pts) wet AMD top-line data expected mid-2026; LUCIA (475 pts) data to follow.
Phase 3 DME program (COMO/CAPRI) first patient dosing expected Q1 2026; ~240 pts each.
Preliminary cash & investments ~$300M at Dec 31, 2025; runway into Q4 2027.
DSMC second review recommended continuation of Phase 3 program with no protocol changes.
Presenting at J.P. Morgan Healthcare Conference on Jan 13, 2026 at 7:30 a.m. PT.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.